Publications by authors named "M Carmen Arenas"
Hemodialysis (HD) is a treatment with a significant environmental impact. One dialysis cycle is equivalent to the daily consumption of 3.5-4 people, and the average annual electricity consumption of a center is equivalent to that of approximately 2.
View Article and Find Full Text PDFArticle Synopsis
- Despite clinical guidelines recommending lower use of central venous catheters (CVC), the prevalence remains high among patients undergoing hemodialysis, leading researchers to explore whether this is due to unavoidable circumstances or factors that can be addressed.
- A study involving 637 chronic hemodialysis patients from various centers in Spain sought to identify modifiable factors influencing CVC use, comparing demographics, vascular access types, and reasons patients had for not using arteriovenous fistulas (AVF).
- Results showed that 40% of the patients utilized CVCs, with major reasons for CVC use including patient refusal for surgery (often due to fear) and having initiated hemodialysis with a CVC, indicating that
: The management of early breast cancer (BC) includes surgery, followed by adjuvant radiotherapy, chemotherapy, hormone therapy, or immunotherapy. However, the influence of these interventions in metabolic reprogramming remains unknown. This study explored alterations in the plasma metabolome of BC patients following distinct treatments to deepen our understanding of BC pathophysiology, outcomes, and the identification of potential biomarkers.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the combined effects of GHRH-R antagonist MIA-690 and EGFR inhibitor Gefitinib on advanced prostate cancer cells, as treating castration-resistant prostate cancer (CRPC) is challenging due to drug resistance.
- Findings show that this combination therapy significantly reduces cell viability, adhesion, and metalloprotease activity, while also causing cell cycle arrest in prostate cancer PC-3 cells.
- In vivo results from athymic nude mice confirm that the combined treatment is more effective against tumors than using either drug alone, by disrupting the interaction between GHRH-R and EGFR pathways.